

SESSIONS

DAY 1 - 28/03/2019

Registration

08:00 - 08:50

Chairman's Opening Remarks

08:50 - 09:00

Approaching the Human Body Differently: Microbiome Therapeutic areas and moving the path forward

09:00 - 10:00

Microbiome Therapeutics Europe

This session will cover clinical development, research, and future direction of the human microbiome frontier.

Participants

Ricardo Valladares - Vice President, Research & Development, Siolta Therapeutics

Early life Microbiome Development: the Interaction of Fungal Species with Diet and Bacteria

10:00 - 10:30

Microbiome Therapeutics Europe

This session will cover studies on early life microbiome development, especially the part of the microbiome that concern fungi in pre-term children, and correlated fungal and bacterial composition to health risks such as NEC and sepsis. This will cover findings in the implication of pre-term birth, the extensive use of antibiotics in early life, and fungi composition in the early life intestinal compartment, highlighting the mechanistic elements of fungi-epithelial function which is relevant for later risks of immune mediated chronic diseases in adulthood.

This session will also consider project lines on microbiota predictive biomarkers in postoperative ileus and anastomotic leakage, in adult patients.

Participants

Wouter De Jonge - Professor of NeuroGastroenterology, AMC Amsterdam

Morning Coffee and Networking

10:30 - 11:00

Microbiome Therapeutics Europe

Single-cell dispensing technology – a new tool for isolation and cultivation

11:00 - 11:45

Microbiome Therapeutics Europe

This session will cover technology for label-free cell isolation. B. sight, a benchtop instrument for automated isolation of prokaryotic cells, single-cell dispensing technology, and how it can be used to isolate single bacteria from heterogeneous samples such as faeces or sputum for subsequent clonal cultivation or single-cell sequencing. The technology could be an ideal tool for isolation and cultivation of potentially unknown microbial species.

Participants

Julian Riba - CSO, Cytena

Paragen: Unique Collection to Modulate Microbiome Composition

11:45 - 12:15

Microbiome Therapeutics Europe

This session will cover collection, R & D and Emerging Technologies for Microbiome Drug Development

Participants

Philippe Galant - CSO, SYNGULON

Lunch and Networking

12:15 - 13:15

Microbiome Therapeutics Europe

Engineering the Microbiome: Targeted Bacterial CRISP-Cas proteins

13:15 - 13:45

Microbiome Therapeutics Europe

This talk will cover the disruptive approach into engineering the microbiome by delivering genetic circuit expressing CRISP-Cas or other proteins into targeted bacterial populations of the microbiome.

Participants

Xavier Duportet - CEO, Eligo Bioscience

Microbiome Therapeutics Europe

28 - 29 March 2019

Courtyard by Marriott Vienna Prater/Messe
Vienna

How can we talk about health care when we don't understand health and we don't care?

13:45 - 14:30

Microbiome Therapeutics Europe

The emerging science of the microbiome is still in its infancy yet it is the driving force behind a transformative scientific revolution. What lies ahead will have broad implications for us as scientists, our companies and academic institutions, our health, and perhaps for our survival. It is worth reflecting on where we are today, how we got here, what we have learned so far, and the limitations of our methods and of our vision. I will present some of the microbiome data from our recent Amazon studies of minimally impacted Yanomami hunter-gatherers, discuss what we are learning about our biological past that is challenging our deeply held ideas about human health.

Participants

Larry Weiss - CEO & Founder, Persona Biome

Microbiome Reference Standards: A Path from Research to Therapeutics Through Higher Quality of Data

14:30 - 15:00

Microbiome Therapeutics Europe

This session will identify new bio-markers that may serve as disease indicators and to understand biologically-relevant properties of the human gut microbiome, validated measurements that accurately describe various properties of the microbial community are needed, both quantitatively and qualitatively. The availability and compulsory use of the whole stool gut microbiome reference material as well as other reference materials would enable researchers to advance microbiome science through measurement assurance further and faster. While some efforts are currently moving in this direction directed in this area, no clear consensus on methods and criteria for control reagents exists. This session will discuss the current state of the art and novel products in the pipeline as well as suggested uses and scope of applications.

Participants

Raul Cano - CSO, The BioCollective

Coffee and Networking

15:00 - 15:30

Microbiome Therapeutics Europe

The status of microbiome-derived therapeutics, R&D, new technologies and applications

15:30 - 16:00

Microbiome Therapeutics Europe

Participants

Michel de Baar - Executive Director, Business Development, Europe, Merck

SESSIONS

DAY 1 - 28/03/2019

Microbiome Therapeutics Europe

28 - 29 March 2019

Courtyard by Marriott Vienna Prater/Messe
Vienna

Showcase Spotlight

16:00 - 17:00

Microbiome Therapeutics Europe

Networking Drinks Reception

17:00 - 18:00

End of Conference Day 1

18:00 - 18:05

SCHEDULE

DAY 1 - 28/03/2019

Microbiome Therapeutics Europe

28 - 29 March 2019

Courtyard by Marriott Vienna Prater/Messe
Vienna

TIME	MICROBIOME THERAPEUTICS EUROPE
08:00	08:00 - Registration 08:50 - Chairman's Opening Remarks
09:00	09:00 - Approaching the Human Body Differently: Microbiome Therapeutic areas and moving the path forward
10:00	10:00 - Early life Microbiome Development: the Interaction of Fungal Species with Diet and Bacteria 10:30 - Morning Coffee and Networking
11:00	11:00 - Single-cell dispensing technology – a new tool for isolation and cultivation 11:45 - Paragen: Unique Collection to Modulate Microbiome Composition
12:00	12:15 - Lunch and Networking
13:00	13:15 - Engineering the Microbiome: Targeted Bacterial CRISP-Cas proteins 13:45 - How can we talk about health care when we don't understand health and we don't care?
14:00	14:30 - Microbiome Reference Standards: A Path from Research to Therapeutics Through Higher Quality of Data
15:00	15:00 - Coffee and Networking 15:30 - The status of microbiome-derived therapeutics, R&D, new technologies and applications
16:00	16:00 - Showcase Spotlight
17:00	17:00 - Networking Drinks Reception
18:00	18:00 - End of Conference Day 1

SESSIONS

DAY 2 - 29/03/2019

Microbiome Therapeutics Europe

28 - 29 March 2019

Courtyard by Marriott Vienna Prater/Messe
Vienna

Chairperson's Opening Remarks

08:45 - 09:00

Emerging Microbial Therapeutics - Moving Beyond the Gut

09:00 - 09:30

Microbiome Therapeutics Europe

Siolta Therapeutics, an emerging biotech company in San Francisco, has developed a systems approach to live biotherapeutic product (LBP) development for the prevention and treatment of inflammatory diseases. Their proprietary platform provides 1) patient stratification, 2) immunomodulatory assessment, and 3) rationally engineered microbial therapeutics for targeted treatments. Siolta's current focus is on the clinical development of its lead product to prevent and treat allergic asthma.

Participants

Nikole Kimes - Founder/Vice President, Siolta Therapeutics

Metatranscriptomic technology: data-driven personalized nutrition and medicine

09:30 - 10:00

Microbiome Therapeutics Europe

This presentation will describe a clinical metatranscriptomic method for stool analysis, Viomega. It will also cover the application of Viomega on human stool samples toward personalized nutrition and medicine. Viomega was specifically developed for population-scale studies on the effects of gut microbiome on human health and disease. This technology can be applied to any clinical sample. It has already received a CLIA license (similar to IVD in EU) for human stool samples. We have applied Viomega to >10000 human stool samples and >1000 human blood samples.

Viomega includes sample collection, ambient temperature sample preservation, total RNA extraction, physical removal of ribosomal RNAs (rRNAs), preparation of directional Illumina libraries, Illumina sequencing, taxonomic classification based on a database of >110,000 microbial genomes, and quantitative microbial gene expression analysis using a database of ~100 million microbial genes. Viomega shows >98% accuracy in clinical validation tests and 100% accuracy when applied to a known microbial community.

This session will show data from 10,000 human stool samples and several clinical studies that reveal the connections between diet and gut microbiome. We wish to make Viomega available to researchers and companies to advance personalized nutrition and medicine.

Participants

Momo Vuyisich - Chief Science Officer, Viome, Inc

Infant studies and application

10:00 - 11:00

Microbiome Therapeutics Europe

Participants

David Kyle - Chairman and CSO, Evolve Biosystems Inc.

Morning Coffee and Networking

11:00 - 11:30

Microbiome Therapeutics Europe

Ammonia Oxidizing Bacteria for the treatment of inflammatory disorders

11:30 - 12:30

Microbiome Therapeutics Europe

Participants

Todd Krueger - Chief Executive Officer and President, AOBiome

Developing industry standards for the Microbiome Therapeutics

12:30 - 13:00

Microbiome Therapeutics Europe

Appreciation for the role of microbes in our lives has been growing rapidly, but the measurement science needed to understand and fully exploit microbial systems has developed at a much slower pace than the industries dependent on them demand. NIST is developing standards for microbiome measurements that will enable federal, academic, and industry labs to reliably reproduce and advance each other's results. Microbiome standards will support research investigations and commercial translation of microbiome science by providing measurement assurance tools: standardized protocols, reference materials, validated measurements and critically evaluated reference data

Participants

Scott Jackson - Leader – Complex Microbial Systems Group, Biosystems and Biomaterials Division, National Institute of Standards and Technology

Lunch and Networking

13:00 - 14:00

Microbiome Therapeutics Europe

Keynote Speaker: Innovative approaches and Clinical Pipelines

14:00 - 14:30

Microbiome Therapeutics Europe

Invited: *Lee Jones, CEO, Rebiotix*

Important Early Considerations to Developing a Successful Commercial Strategy

14:30 - 15:15

Since the Human Microbiome Project and the advancement of next generation sequencing (NGS), we now know that our microbiome plays an important part in our physiology and its relationship to diseases. The field of the microbiome has taken off and numerous startups are trying to use the microbiome to develop treatments or cures for various diseases. However, this field is in its infancy and a successful commercialization of microbiome products has yet to be proven. There are a number of factors to consider early in product development that are critical to developing a commercial strategy. These factors can also influence regulatory, clinical development and even manufacturing strategies. Find out what factors need to be considered early in product development in order to develop a success commercial strategy.

Participants

Regina Au - Principal, BioMarketing Insight

Distribution Case Study: DNA and RNA Purification Products and Tools

15:15 - 15:45

Brought to you by Zymo Research

Prebiotics and Probiotics Across Continents: Working Together

15:45 - 16:15

End of Conference Day 2

16:15 - 16:20

SCHEDULE

DAY 2 - 29/03/2019

Microbiome Therapeutics Europe

28 - 29 March 2019

Courtyard by Marriott Vienna Prater/Messe
Vienna

TIME	MICROBIOME THERAPEUTICS EUROPE
08:00	08:45 - Chairperson's Opening Remarks
09:00	09:00 - Emerging Microbial Therapeutics - Moving Beyond the Gut 09:30 - Metatranscriptomic technology: data-driven personalized nutrition and medicine
10:00	10:00 - Infant studies and application
11:00	11:00 - Morning Coffee and Networking 11:30 - Ammonia Oxidizing Bacteria for the treatment of inflammatory disorders
12:00	12:30 - Developing industry standards for the Microbiome Therapeutics
13:00	13:00 - Lunch and Networking
14:00	14:00 - Keynote Speaker: Innovative approaches and Clinical Pipelines 14:30 - Important Early Considerations to Developing a Successful Commercial Strategy
15:00	15:15 - Distribution Case Study: DNA and RNA Purification Products and Tools 15:45 - Prebiotics and Probiotics Across Continents: Working Together
16:00	16:15 - End of Conference Day 2